Thus, it seems that screening diagnosis of ovarian cancer should be supplemented by GLO1, TUFT1, and UBA2 determination and assessment of the risk of loss of adequate response to chemotherapy by GLO1 mRNA expression pattern determination. This evidence concerns the gene GLO1 and ovarian carcinoma.